Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPS10-NUDT3 is a fusion protein resulting from a naturally occurring read-through event between the *RPS10* and *NUDT3* genes on human chromosome 6. The read-through transcript produces a chimeric protein sharing sequences from both parent proteins—RPS10, a component of the ribosomal small subunit involved in protein synthesis, and NUDT3, a Nudix hydrolase implicated in nucleoside diphosphate metabolism and cellular homeostasis. The precise molecular and biological function of this read-through fusion protein remains unclear. It is not currently an established therapeutic target, lacks drug-gene interaction evidence, and is not employed as a biomarker or in clinical settings[1][2][3][4][5][6][7]. If you require structured data for RPS10 or NUDT3 individually, more established therapeutic, functional, and pharmacological data are available for the parent proteins.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RPS10-NUDT3 readthrough protein (RPS10-NUDT3).